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Prolonged (post-thaw) shelf life of −80°C frozen AB apheresis
plasma
Tim W.H. Rijnhout ,1,2 Femke Noorman,3 Margreet Zoodsma,3 Bob De Kort,3 and Rigo Hoencamp1,2,4,5
BACKGROUND: Early plasma transfusion is important
in the treatment of patients with major hemorrhage.
Prolonged shelf life of AB type frozen −80°C and cold-
stored (4°C) deep frozen plasma (DFP) will improve
strategic stock management, minimize need for resupply,
and make pre-hospital implementation more feasible.
METHODS AND MATERIALS: Plasma products type
AB of different age and origin (−30°C Fresh Frozen
[(FFP], −80°C DFP [short (1 year) and long (7 year)]
stored) were thawed (Day 0), stored at 4°C, and sampled
on Days 7 and 14. Additionally, samples of plasma
containing blood products (Octaplas LG®, whole blood
and platelets) were compared for coagulation factor
activity, phospholipid clotting time (PPL), and kaolin TEG
during 4°C or 22°C storage.
RESULTS: Coagulation profiles of FFP, short- and long-
stored −80°C DFP were not significantly different after
thaw. Cold storage did not affect fibrinogen, Protein C,
and Antithrombin III activities whereas factor V, VII, VIII,
and Protein S decreased in all blood products. After
14 days DFP still meets the guidelines for clinical use,
except for Protein S (0.4 IU/mL). With exception of
Octaplas LG®, phospholipid activity and TEG
coagulation were similar between plasma containing
blood components during storage.
CONCLUSION: AB DFP quality was unaffected by
almost 7 years of frozen storage. Quality of thawed 14-
day stored AB DFP met, with exception of Protein S, all
minimal guidelines which implies that its quality is
sufficient for use in the (pre)-hospital (military)
environment for treatment of major hemorrhage.
I
n the treatment of major hemorrhage, the doctrine
shifted from transfusing significant quantities of red
blood cells (RBCs) and crystalloids before laboratory-
based plasma and platelet transfusion, to immediate
goal-directed resuscitation with all blood components in a
ratio that equals whole blood (WB) until the patient is
hemodynamically stable.1,2 Especially during massive trans-
fusion, rapid availability of blood components and prudent
crystalloid use is advocated to prevent or ameliorate the
effects of hemodilution and coagulopathy.
Early plasma transfusion is beneficial for survival in
patients with major hemorrhage, it is therefore widely advo-
cated and has been used in different forms and quantities.
It contains clotting factors, clotting inhibitors, albumin,
immunoglobulins, and other components essential to main-
tain hemostasis and vascular integrity, including the
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regulation of coagulation and fibrinolysis. However, due to
the limited shelf life of 3-4 weeks at 4°C, plasma is mostly
frozen as soon as possible after donation to extend its shelf
life. With a thawing time of approximately 15-35 minutes
(pending on volume and temperature frozen) it is not
immediately available.
Availability of thawed plasma offers opportunities to
reduce time to first plasma transfusion and to implement
plasma transfusion in the (pre)-hospital setting.3-5 Multiple
study groups have shown that prolonged 4°C storage of
thawed plasma led to a reduction in clotting factors and
argued that quality is still sufficient for treatment of major
hemorrhage.6-14
The Dutch Ministry of Defense (D-MOD) has used
−80°C AB type apheresis deep frozen plasma (DFP) since
2001 and its use is shown to be safe and effective.15,16 Cur-
rently, DFP can be stored frozen (−80°C) for up to 7 years
and cold stored (+4°C) up to 7 days post-thaw.15,17 Intro-
duction of 7-day cold-stored DFP in Afghanistan resulted in
140 (1-5 per patient) transfused units with an average prod-
uct age of 4 days. Additionally, DFP use resulted in earlier
plasma and platelet use which was associated with reduced
mortality.15
The aims of this study are to extend shelf life of both
frozen and thawed DFP for the treatment of major hemor-
rhage. Increased shelf life of frozen and thawed DFP will
result in more efficient strategic stock management and cre-
ate possibilities to reduce production frequency to maintain
a stockpile of DFP, minimize need to resupply hospitals,
reduce the logistic burden and improve the availability of
universal donor plasma for early use in (pre-) hospital care.
METHODS AND MATERIALS
Study design
Both long and short −80°C stored (1 vs. almost 7 years) AB
DFP are compared to fresh thawed AB FFP. Additionally,
AB DFP quality is compared with other plasma containing
universal donor type blood products (AB Octaplas®, O WB,
A platelets) used during resuscitation. To test the hypothesis
that the maximum allowed −80°C and post-thaw 4°C shelf
life can be doubled, short- and long-stored products were
compared with each other and with the European Director-
ate for the Quality of Medicines (EDQM) guidelines for fresh
frozen plasma (FFP) or pathogen-reduced FFP (PR-FFP)
(see Appendix S1, available as supporting information in the
online version of this paper.).18
Comparison of plasma storage results
Short- (1 year) and long- (7 years) stored units of −80°C
DFP were thawed and compared to 1 year 30°C stored
FFP directly after thaw. Additional testing was performed
for both types of DFP on Day 7 (D7) and Day 14 (D14) of
storage at +4°C after thaw.
DFP vs. other blood (components)
As plasma of platelets and WB contribute to the treatment
of bleeding patients these products are included in this
study. DFP was compared to −30°C S/D treated AB type
plasma (omniplas (OMN); Octaplas® LG made from Dutch
FFP, Octapharma GmbH, Langenfeld Germany), cold-stored
O type CPD WB without (WB0) and with leukodepletion
(WBF), and A type leukodepleted pooled buffy coat throm-
bocyte concentrates in plasma (BTC) or in additive solution
(BAS). BAS units contain 35% plasma and 65% Platelet
Additive Solution-E (PAS-E). All products were analyzed
and compared during 4°C/22°C storage.
Based on the Blood Supply Act, Sanquin is the only
organization in the Netherlands authorized to manage the
need for blood and blood products. For this reason,
Octaplas LG ® and DFP are made from FFP that is procured
from Sanquin. WB and platelet products used in this study
were obtained from Sanquin after informed consent from
the donors. Eight samples (N = 8) of each product was
compared.
Production and quality control of DFP
Leukocyte-depleted apheresis plasma (AB-Rh D positive
and negative) is fresh frozen and stored at −30°C for a mini-
mum of 4 months by Sanquin (FFP). After release from
quarantine and delivery to the Military Blood Bank (MBB)
the product is stored at −30°C till production of DFP; FFP is
thawed in a temperature controlled 37°C water bath until a
temperature of 28-32°C is reached and subsequently trans-
ferred into a new 600 mL PVC bag (Macopharma, Utrecht,
The Netherlands), vacuum sealed in an overwrap, packed in
a cardboard box and re-frozen on the bottom of an empty
−86°C chest freezer (Snijders Labs, Tilburg, The Nether-
lands) to freeze the products at a rate of 1-5°C/min to −80°
C. Hereafter the DFP are transferred to upright −86°C
freezers (Snijders) for long term −80°C storage. Tempera-
tures of freezers are continuously monitored to guarantee a
temperature below −65°C at all times.
Periodically, samples are drawn from the FFP during
production of DFP for quality control (QC) purposes. Simi-
larly, DFP produced by the MBB was periodically thawed
for QC purposes. After −80°C storage, units of DFP were
thawed for 25-35 minutes in a temperature-controlled water
bath (37°C) until a temperature of 28-32°C is reached and
after sampling the product was stored at 4°C and sampled
again on D7 and D14. QC data of the period 2018-2019 are
used in this study.
Blood product comparison study
For the comparison experiment (period 2018-2019), n = 8,
short-stored DFP were compared to AB OMN (2 different
batches, 2 yr frozen and  4 yr frozen, N = 4/batch) and
the supernatant plasma of three different plasma containing
blood components. Fresh thawed DFP and OMN were split
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in equal portions in 150 mL PVC sample bags (TerumoBCT
Leuven, Belgium) and analyzed on Day 0 (D0) and after 4°C
storage D7 and D14. WB products (n = 16) were shipped 1
day after donation and donor testing to the MBB; half of the
units were leukodepleted by filtration (WBF) with a platelet
sparing filter (Imuflex® WB-SP TerumoBCT, Leuven Bel-
gium), the other half was not leukodepleted (WB0). Subse-
quently, all units were split and stored in 150 mL PVC bags
at 4°C before analysis on Day 2 (D2), D14, and Day 21
(D21). BTC and BAS units (n = 8 each) were shipped to the
MBB on Day 1 (D1) after donation, donor testing, and
processing by Sanquin. One 120 mL sample was stored for
14 days at 4°C and the rest of the product was stored in the
original bag at 22°C under constant agitation before sam-
pling and analysis on D2 and D7.
Sample analysis
All measurements were performed within 6 hours of sam-
pling/removal from storage. The number of products mea-
sured each day did not exceed 12 and the same reagent lot
numbers were used for QC and comparison studies. QC
samples of FFP, DFP, and OMN were analyzed without pre-
analysis centrifugation or filtration. In the comparison
study, all product samples were filtered with a 200 μm
transfusion filter (Codan transfusion set, Lensahn, Ger-
many) prior to analysis. FFP, OMN, and DFP were analyzed
directly, whereas WB and BTC samples were first cen-
trifuged (2500 g, 15 min) to obtain supernatant plasma for
coagulation analysis. Samples were analyzed with the Sta
Compact Max 3 (Stago BNL, Leiden, The Netherlands) for
coagulation factor profiles according to the manufacturers’
instructions. Furthermore, the Sysmex XS1000i Hematologi-
cal analyzer (Sysmex, Etten-Leur, the Netherlands) was used
to measure concentration. Stago phospholipid (PPL) activity
(measures coagulation time of a sample diluted in buffer
and PPL deficient plasma, activated with Calcium and acti-
vated factor X) and Kaolin TEG (TEG 5000, Haemonetics,
Breda, the Netherlands) were measured of pure plasma and
of microparticle rich supernatant of plasma (1 × 2500 g
15 min) or microparticle rich supernatant of cellular blood
products (2 × 2500 g 15 min).19 Not all QC samples were
measured for all coagulation factors daily, as a result of tem-
porarily insufficient consumable items on different QC days.
Outcome measures
Coagulation factor activators and inhibitors (factor V, VII,
VIII, Protein C, Protein S, Antithrombin III [ATIII]) were
compared with European EDQM guidelines 2017 for fresh
FFP; average factor VIII activity ≥0.7 IU/mL in ≥90% of the
products measured within 1 month of −30°C frozen storage
and with guidelines for PR-FFP; average factor VIII activity
≥0.5 IU/mL and fibrinogen activity ≥60% of fresh donor
plasma, in ≥90% of the products measured within 1 month
of −30°C frozen storage. In the accompanying text it is
stated that PR-FFP “contains, on average, about 50 to 70% of
the labile coagulation factors and naturally occurring inhibi-
tors present in fresh unfrozen/thawed plasma.”18 The per-
centage of products that comply with these guidelines was
determined for all product categories. In addition, coagula-
tion times APTT, INR, phospholipid (PPL) clotting time, and
TEG-profiles were assessed.
Statistical analysis
Statistical calculations were performed using SPSS (version
25, IBM or higher). Shapiro–Wilk test was used to assess the
normality of the data distribution. Normal distributed data
are expressed with mean and 95% confidence upper and
lower limits, t-tests were used to determine significant dif-
ferences. Not normally distributed data are expressed as
median and 95% confidence upper and lower limits, Mann
TABLE 1. Quality control data 2018-2019; FFP and DFP coagulation factor profiles after thaw; effect of −80°C storage
duration
FFP (n = 68) DFP short stored (n = 37) DFP long stored (n = 42)
Years at −30°C 0.6 [0.6-0.6] †,‡ 0.7 [0.7-0.8] *,‡ 1.0 [0.9-1.0] *,†
Years at −80°C ND 0.1 [0.1-0.2] *,‡ 5.8 [5.7-6.1] *,‡
Volume mL 305 [304-306] †,‡ 294 [291-297] *,‡ 299 [296-301] *,†
Plt count 109/L 10 [7-13] 14 [10-21] 13 [7-20]
MPV (fL) 10.1 [9.8-10.3] †, ‡ 7.6 [6.9-8.2] * 7.4 [7.3-7.6] *
APTT sec 31 [31-32] ‡ 31 [31-32] 32 [32-33] *
INR 1.1 [1.1-1.2] 1.1 [1.1-1.2] 1.1 [1.1-1.2]
Fibrinogen gr/L 3.0 [3.0-3.1] 3.0 [3.0-3.2] 3.0 [2.8-3.5]
FV IU/mL 1.0 [1.0-1.1] n = 64 0.9 [0.9-1] 1.0 [1.0-1.1]
FVII IU/mL 1.0 [1.0-1.1] n = 60 1.0 [1.0-1.1] 1.0 [1.0-1.1]
FVIII IU/mL 1.2 [1.2-1.3] n = 49 1.1 [1.1-1.4] 1.0 [0.9-1.2]
Protein S IU/mL 1.0 [1.0-1.1] n = 51 1.0 [1.0-1.1] 1.0 [1.0-1.2]
Protein C IU/mL 1.2 [1.2-1.3] n = 45 1.2 [1.2-1.3] 1.2 [1.2-1.3]
ATIII IU/mL 1.0 [1.0-1.1] n = 59 1.0 [1.0-1.1] 1.0 [1.0-1.1]
Data are presented as median-[95%LCL-UCL]); All products are within EDQM guidelines for 1 month stored FFP (<10% of units. Coagulation
factors<0.65 IU/mL). Bonferroni correction p value< alpha 0.05/3 = 0.0167.
*,†,‡ = p < 0.0167 Mann Whitney test vs. respectively FFP, DFP short and long stored at −80°C.
FFP = fresh frozen plasma; DFP = deep frozen plasma.
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TABLE 3. QC data 2018-2019; Nr and percentage of FFP and DFP products not within EDQM guidelines after thaw and
during 4°C post-thaw storage
FFP DFP (short and long stored at −80°C)
Days at 4°C 0 0 7 14
Platelets<50 109/mL *, § 2/68 (3%) 2/79 (3%) 9/79 (11%) 12/67 (18%)
FVIII<0.65 IU/mL † 0/49 (0) 0/79 (0) 26/79 (33%) 30/79 (38%)
FVIII<0.45 IU/mL § 0/49 (0) 0/79 (0) 1/79 (1%) 2/79 (3%)
FV < 0.45 IU/mL § 0/64 (0) 0/79 (0) 1/79 (1%) 2/79 (3%)
FVII<0.45 IU/mL § 0/60 (0) 0/79 (0) 1/79 (1%) 0/79 (0)
FVII≥1.45 IU/mL ‡ 0/60 (0) 1/79 (1%) 3/79 (4%) 12/79 (15%)
Protein S < 0.45 IU/mL § 0/51 (0) 0/79 (0) 10/79 (13%) 58/78 (74%)
Protein C < 0.45 IU/mL § 0/45 (0) 0/77 (0) 0/79 (0) 0/70 (0)
Fibrinogen<1.75 gr/L § 0/68 (0) 0/79 (0) 0/79 (0) 0/79 (0)
ATIII <0.45 IU/mL § 0/59 (0) 0/79 (0) 0/79 (0) 0/79 (0)
Number of products not within guidelines.
* Guidelines EDQM-FFP before freezing.
† Guidelines EDQM-FFP after 1 month at −30°C.
‡ Not in EDQM guidelines.
§ EDQM-pathogen reduced FFP /total number of products after 1 month at −30°C(%).
TABLE 4. QC data 2018-2019; FFP and DFP Phospholipid (PPL) coagulation time and kaolin-TEG profile after thaw and
during 4°C post-thaw storage
PPL* Sec TEGR min TEG angle ° TEG MA mm
FFP day 0 n = 68 41 (40-43) † 9 [8-9] † 68 [67-71] † 28 [27-30]
DFP <5y day0 n = 37 46 (43-48) 9 [9-10] 65 [64-68] 27 [25-30]
DFP >5y day0 n = 42 49 (47-51) 10 [9-10] 65 [62-68] 27 [25-31]
DFP day 0 n = 79 47 (46-49) ‡ 9 [9-10] ‡ 65 [64-68] 27 [26-30] ‡
DFP day 7 n = 79 57 (55-59) ‡ 11 [10-11] ‡ 63 [62-66] 28 [28-30]
DFP day14 n = 67 64 (62-66)§ 11 [10-11] ‡ 65 [64-67] 29 [29-32] ‡
Data are presented as median [95% Lower confidence interval – Upper confidence interval].
* PPL normally distributed data represented as mean - (95% Lower confidence interval – Upper confidence interval) Bonferroni correction p
value< alpha 0.05/6 = 0.0083.
† p < 0.0083 Mann Whitney. test FFP vs. DFP (short or long stored, Day 0,7 or 14 (PPL t-test).
‡ p < 0.0083 Mann Whitney. DFP day 0 vs. DFP Day 7 or 14 (PPL t-test).
§ p < 0.0083 t-test DFP day 7 vs. DFP Day 14 (PPL).
TABLE 2. Quality control data 2018-2019; FFP and DFP plasma coagulation factor profile; effect of post-thaw 4°C
storage on thawed DFP
FFP n = 68 DFP = 79 (short and long stored at −80°C)
Days at 4°C 0 0 7 14
plt count 109/L 10 [7-13] *,† 14 [10-20] 20 [15-24] 21 [15-28]
MPV (fL) 10.1 [9.8-10.3] *,† 7.4 [7.3-7.6] 7.6 [7.2-8.0] * 7.6 [7.1-8.0] †
Fibrinogen gr/L 3.0 [3.0-3.1] 3.0 [2.9-3.2] 3.1 [3.0-3.3] 3.0 [3.0-3.2
APTT sec 31 [31-32] *,† 32 [32-33] §,|| 35 [35-36] ‡ 35 [35-36] ‡
FVIII IU/mL 1.2 [1.2-1.3] *,† 1.0 [1.0-1.1] §,|| 0.7 [0.7-0.8] ‡ 0.7 [0.7-0.9] ‡
INR 1.1 [1.1-1.2] *,† 1.1 [1.1-1.2] §,|| 1.3 [1.3-1.4] ‡ 1.3 [1.3-1.4] ‡
FV IU/mL 1.0 [1.0-1.1] *,† 1.0 [1.0-1.1] §,|| 0.8 [0.8-0.9] ‡,|| 0.7 [0.7-0.8] ‡,§
FVII IU/mL 1.0 [1.0-1.1] * 1.0 [1.0-1.1] §,|| 0.8 [0.8-0.9] ‡,|| 0.9 [0.8-1.0] ‡,§
Protein S IU/mL 1.0 [1.0-1.1] *,† 1.0 [1.0-1.1] §,|| 0.6 [0.6-0.7] ‡,|| 0.4 [0.4-0.5] ‡,§
Protein C IU/mL 1.2 [1.2-1.3] † 1.2 [1.2-1.3] 1.2 [1.2-1.4] 1.1 [1.1-1.2]
ATIII IU/mL 1.0 [1.0-1.1] 1.0 [1.0-1.1] 1 [1-1.1] 1.0 [1.0-1.1]
Data are displayed as median 95% LCL-UCL; Bonferroni correction p value< alpha 0.05/6 = 0.0083.
Exact n value of DFP not shown, for exact number measured see Table 3.
FFP *,† = p < 0.0083 Mann Whitney test FFP vs. respectively DFP Day 7 or 14.
DFP ‡,§,|| Mann Whitney test p < 0.0083 DFP vs. respectively DFP day 0,7 or 14.
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Whitney tests were used to determine significant
differences.
RESULTS
Presentation of results is separated in quality control (QC)
data (68 units of FFP, 37 units of short stored DFP, and
42 units of long stored DFP) and data from product
comparisons of DFP, OMN, and supernatant plasma from
WB0, WBF, BTC, and BAS (8 units per products). Data were
not distributed normally with exception of PPL clotting time
and are presented accordingly.
Effect of frozen storage on DFP quality
Table 1 compares product characteristics and coagulation









































































































































































































































































































































































































































































































































Fig 1. Coagulation factors in plasma, comparison of products (n = 8). Coagulation factor activities measured in plasma (DFP, OMN) and
supernatant plasma of 1 × 2500 g 15 min centrifuged cellular blood components. DFP, −80°C apheresis plasma; OMN, omniplasma;
WB0, whole blood; WBF, leukodepleted whole blood; BTC, leukodepleted buffy coat pool platelets in 100% plasma; BAS, leukodepleted
buffy coat pool platelets in 65% platelet additive solution E/35%plasma. Gray line = QC FFP value after thaw (see Table 1), dotted
line = 70% activity (0.7 IU/mL) intermittent fat line = Minimum EDQM guideline PR-FFP: 50% activity (0.5 IU/mL) or 60% fibrinogen
(1.8 gr/L). [Color figure can be viewed at wileyonlinelibrary.com]
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Median storage time at −30°C was significantly longer in
both short- (0.7 year) and long-stored DFP (1 year) in com-
parison with FFP (0.6 years) (p < 0.0167). Median additional
−80°C storage time was 0.1 and 5.8 years, which added up
to a median total storage time of 0.9 and 6.8 years for short-
and long-stored DFP respectively. Immediately after thaw,
only APTT was significantly increased (1 second) in longer
stored DFP. All FFP and DFP units contained an average
coagulation factor activity of ≥0.7 IU/mL after thaw.
Effect on DFP quality during post-thaw +4°C
storage
During post-thaw cold storage there were no significant dif-
ferences between short and long stored DFP (data not
shown). Table 2 compares clotting factors, inhibitors. and
clotting times between fresh thawed FFP and thawed DFP
(short and long stored) during post-thaw cold storage. No
statistically significant differences were found between DFP
and FFP on D0 after thaw except a decreased mean platelet
volume (MPV) in DFP. There were significant reductions in
coagulation activity of factor V, VII and VIII, Protein S, and
significant increases in APTT and INR during post-thaw cold
storage of DFP, whereas platelet count and MPV non-signif-
icantly increase and fibrinogen levels, Protein C and ATIII
remained stable.
Table 3 summarizes the number and percentage of
units that did not meet minimum quality thresholds set by
the EDQM for fresh thawed (PR-)FFP. At D7 and D14, units
of DFP did not meet these guidelines for platelet count (11-
18%) and Protein S (13-74%). In some plasma units factor
VII increased to above normal during cold storage. Table 4
shows the phospholipid coagulation times and kaolin-TEG
profiles. PPL clotting time, TEG R time, and TEG MA signifi-
cantly increased during post-thaw storage (p < 0.0083).
Comparison of plasma containing blood products
Figure 1 and Appendix S2, available as supporting informa-
tion in the online version of this paper, lists main characteris-
tics and trend of clotting factor profile in plasma containing
blood components. The total number of products not meet-
ing quality thresholds is shown in Table 5. ATIII and Protein
C activities were not affected by cold storage in any product,
and except in BAS, both inhibitor activities were between 0.9-
1.3 IU/mL (data not shown). Directly after thaw, Protein S in
OMN is below the minimum EDQM threshold for PR-FFP
(0.5 IU/mL). At D7, OMN Protein S, BTC factor V, and Pro-
tein S no longer met these guidelines. After 14 days of cold
storage, factor VIII was below this guideline in all products
except in OMN and BTC. BAS did not meet (PR-)FFP guide-
lines at all. In some DFP, almost all OMN and one WB0 fac-
tor VII increased to above normal during cold storage.
OMN showed no clot formation in TEG within
30 minutes and no clot formation in PPL within 120 seconds
(see Appendix S3, available as supporting information in the
online version of this paper.). Supernatant PPL clotting time
increased in thawed DFP and decreased for both types of
WB and platelets during storage, however, supernatant TEG
R time was not significantly shortened in the cellular blood
products during storage. Supernatant TEG angle reduced
for DFP and showed an increase for BAS during storage.
TABLE 5. Nr of plasma containing blood components not within EDQM guidelines after thaw and during (post-thaw)
storage (n = 8/product)
FVIII <0.65 IU/mL * FVIII <0.45 IU/mL † FV <0.45 IU/mL † FVII ≥1.45 IU/mL ‡ ProtS <0.45 IU/mL †
DFP after thaw - - - - -
DFP 7 days 4°C 3 - - - 2
DFP 14 days 4°C 5 1 - 2 7
OMN after thaw - - - - 3
OMN 7 days 4°C 8 - - - 8
OMN 14 days 4°C 8 - - 6 8
WB0 2 days 22/4°C 3 2 - - -
WB0 14 days 4°C 8 4 - - 1
WB0 21 days 4°C 8 7 4 1 6
WBF 2 days 22/4°C 2 - - - -
WBF 14 days 4°C 7 3 - - 1
WBF 21 days 4°C 8 4 1 - 2
BTC 2 days 22°C - - - - 1
BTC 7 days 22°C 1 - 4 - 8
BTC 14 days 4°C - - - - 5
BAS 2 days 22°C 8 8 8 - 6
BAS 7 days 22°C 8 8 8 - 8
BAS 14 days 4°C 8 8 8 - 8
DFP, −80°C apheresis plasma; OMN, omniplasma; WB0, whole blood; WBF, leukodepleted whole blood; BTC, leukodepleted buffy coat pool
platelets in 100% plasma; BAS, leukodepleted buffy coat pool platelets in 65% platelet additive solution E/35%plasma.
* Guidelines EDQM-FFP after 1 month at −30°C.
† EDQM-pathogen reduced FFP total number of products after 1 month at −30°C (%).




Patients with major hemorrhage are in need of massive vol-
ume resuscitation. Rapid initiation of a 1:1:1 massive trans-
fusion protocol with early transfusion of (pre-thawed) blood
components and reduced use of crystalloids improve chances
of survival.20 Thawing of plasma often causes delay, making it
difficult to start balanced resuscitation with all blood compo-
nents. Plasma transfusion remains essential since additional
medication such as prothrombin complex concentrate and/or
fibrinogen concentrate is not sufficient to restore or compen-
sate all diluted or lost coagulation factors.21,22
We demonstrated that DFP quality after almost 7 years
of frozen storage was equal in clotting factors and inhibitors
in comparison with fresh thawed 1-year stored FFP and
DFP. The higher platelet count and decreased MPV in
thawed cold stored DFP compared to FFP is probably
related to formation of small microparticles. During cold
storage the platelet count and MPV slightly increase which
indicates swelling and/or fusion of microparticles, thus
becoming large enough to be detected as a ‘platelet’ in the
hematological analyzer. Given the fact that plasma quality
was not affected by 7 years of frozen storage, it is expected
that extending the shelf life at −80°C beyond 7 years will
also not affect plasma quality. This is consistent with results
presented in 2005 by Valeri and colleagues who showed that
14-year −80°C storage of plasma did not cause significant
changes in coagulation factor V, VIII, and fibrinogen
levels.23 We show that there is no reason to discard 7-year
stored AB DFP. Therefore, the MBB has prolonged its stor-
age time to 14 years for now and will continue to monitor
the oldest and newest DFP units in stock with periodical QC
measurements (6 times/year). We will report on outcome
in future studies.
European guidelines for PR-FFP guidelines indicate
that it should contain about 50-70% of labile coagulation
factor and inhibitor activities compared to fresh donor
plasma for clinical use. Guidelines for fresh thawed FFP are
set higher, since this product is also used as a source for the
production of isolated coagulation factors.24 For this reason,
European guidelines state that 90% of 1 month stored −30°
C FFP units should contain factor VIII activity ≥0.7 IU/mL.
Similarly, UK guidelines stipulate a minimum level of
0.7 IU/mL factor VIII activity in 75% of all plasma units
tested, furthermore units found to have <0.3 IU/mL should
not be issued for transfusion.25
There are no guidelines for the minimum quality of
cold-stored (PR-)FFP at the end of storage time. Currently
thawed (PR-)FFP can be stored for 5 days at 4°C. However,
particularly in smaller trauma centers, thawed plasma wast-
age will increase as demand is often too low.6,26 During
(post-thaw) storage all blood products show decreased
clotting factor activities and increased clotting times. DFP
coagulation factor activity still meets fresh thawed PR-FFP
requirements after 14 days of cold storage, except for
Protein S (0.4 IU/mL) which is in line with other studies.6-
9,11,13,27-31
BAS products contain 35% plasma and 65% PAS-E
which explains the low level of clotting factors in this prod-
uct. It is important to consider clinical implications of the
reduced plasma volume when switching to additive solu-
tions for platelet suspension. BAS is still suitable for transfu-
sion since it is primarily transfused for platelet support and
has a higher safety profile, however the product will contrib-
ute less to patient’s clotting factor activities compared to
platelets in plasma. Similarly, it can be argued that although
clotting factors are reduced, 14-day cold-stored thawed DFP
will be primarily used in the early resuscitation of major
hemorrhage instead of crystalloids. Its implementation can
thus result in better patient outcome. In addition, it can be
used by forward surgical teams and reduce the frequency of
resupply, which is especially in military environments
advantageous to minimize risks for material and personnel.
It has been argued that plasma with coagulation factor
activity above 30% of normal is sufficient to support clinical
or surgical hemostasis.32 Most products described in the
current study would comply with the latter prerequisite
except BAS, 7-14-day cold stored OMN, 7 day 22°C stored
BTC and 21 days cold stored WB. Regarding European
guidelines, DFP Protein S activity is below 0.5 IU/mL in
more than 10% of units on day 7 and 14 of cold storage.
However, fresh thawed OMN also did not meet this guide-
line, probably because the OMN used in this study had
been stored for 2-4 years at −30°C. According to the OMN
insert, Protein S level is at 0.6  0.1 IU/mL (n = 5) with a
guaranteed level above 0.2 IU/mL. Low Protein S activity is
caused by the solvent-detergent (S/D) treatment of
Octaplas® and has been improved with the introduction of
Octaplas LG®.11,14 Despite the low Protein S activity, thawed
S/D plasma (e.g., OMN) is successfully used for years in
many countries including The Netherlands.14,33 Although
14-day cold-stored thawed DFP is inferior to fresh thawed
DFP, pre-hospital availability of hemostatic capacity is
important and can be followed with in-hospital transfusion
of fresh thawed plasma. The complex question whether the
early transfusion of cold stored DFP offers advantages rather
than disadvantages because of reduced Protein S activity
remains to be investigated.
A potential concern is the increase in factor VII activity
at D14 in 3 units of DFP, 7 units of OMN and 1 unit of WB0.
Cold activation is associated with an increase in contact and
coagulation systems, however, adverse events in patients
receiving cold activated plasma have not been demon-
strated.33,34 The occurrence of cold activation was previ-
ously reported for all plasma containing blood components
and is more frequent in female plasma, but no related clini-
cal side effects have been reported.35,36 Furthermore,
beyond the scope of this study, blood components are cold
stored in PVC bags containing the plasticizer di(2-
ethylhexyl) phthalate (DEHP), which is soluble in oil and
TRANSFUSION 7
PROLONGED SHELF LIFE OF AB PLASMA
slowly leaks into plasma during 4°C storage.28,37 There are
several concerns regarding the deleterious effects of DEHP,
but toxicology in humans has not been demonstrated and
leakage will occur in all plasma containing blood products
that are cold stored in PVC.
Despite the lack of clinical data to support limitation of
its storage time after thaw and lack of EDQM guidelines for
plasma quality in any cold-stored blood product, the cur-
rent guidelines do mention a maximum 5-day shelf life for
(PR-)FFP after thaw. In the 1980s it was already shown that
prolonged storage time of thawed FFP at +4°C for up to 7 or
14 days is acceptable for clinical use.7,38 More recently,
Tholpady and colleagues argued that clotting factor activity
remained at sufficient levels for up to 10 days.39 Further-
more never frozen plasma can be stored in the United King-
dom for 7 days because of concerns for contact activation,
in Sweden for 7 to 14 days whereas in the US it is approved
for 26 days by the Food and Drug Administration. In 2017,
83000 units were distributed and  14000 units of never
frozen plasma were transfused in the US.40 The current data
of 14 days cold-stored AB DFP show similar clotting factor
activities as reported for 20 days never frozen plasma.41,42
Cold-stored thawed DFP is indeed inferior in compar-
ison with fresh thawed DFP, but similar to that of plasma
in cold-stored WB and platelets. Leukodepletion of WB
with a platelet sparing filter did not affect plasma quality,
which has been observed with other leukodepletion fil-
ters.43,44 Based on the data of this study, WB has equal
fibrinogen content as a unit of apheresis plasma despite its
higher plasma volume, which is due to the higher citrate
dilution of WB compared to apheresis plasma.45 Further-
more universal donor type O required for early transfusion
of WB, has lower factor VIII activities compared to other
blood groups.46 In clinical practice these small differences
in coagulation factor activity will probably have minimal
impact on the clinical outcome of patients with major
hemorrhage. The reduction of plasma in PAS stored plate-
lets may have a significant effect compared to platelets
stored in plasma in this patient category, though this has
yet to be shown.
Supernatant PPL clotting time is performed in buffer to
which sample, activated factor X and PPL deficient plasma
is added. The clotting time decreases with increased micro-
particle concentration in plasma samples.47 Microparticle
content of plasma is thought to be beneficial in the treat-
ment of bleeding trauma patients. This study shows signifi-
cant shorter PPL-time, TEG R time, and TEG angle at
baseline in FFP in comparison with both fresh thawed
short- and long-stored DFP. Likely, this results from the
extra thaw–freeze cycle to produce DFP from FFP, as PPL
activity was not significantly different between short- and
long-stored DFP. It is however questionable if the absence
of PPL activity in OMN, the reduced PPL activity in cold-
stored thawed DFP and fresh cellular blood products com-
pared to fresh thawed FFP and cold-stored cellular blood
products, will have clinical effects in the treatment of these
patients as multiple products of different ages are given in a
fixed 1:1:1 ratio.13,27
Strength and limitations
Different ages and blood types of products makes interpre-
tation of the data presented more difficult. For example,
plasma frozen within 24 hours after extraction from 1-6°C
WB or room temperature stored WB, differ in coagulation
factor VIII and Protein C activity.48,49 In the current study
WB was stored at room temperature overnight before
leukodepletion, splitting and storage at 4°C and BTC were
prepared and stored at 22°C under continuous rotation and
the 4°C sample was drawn and stored 1.5 days after dona-
tion. Routinely processed cold-stored platelets and WB are
likely to be stored at 4°C more quickly after production.
Thus, quality results of routinely processed products may be
better. Furthermore, in the comparison study, all products
(with exception of 22°C stored BTC and BAS) were stored in
sample bags and the smaller volume may have influenced
outcome, although no significant differences were observed
between DFP stored in 600 mL bags or 150 mL bags during
cold storage.
The strength of this study is that only blood types and
products were studied that are actually used in acute resusci-
tation. Furthermore, the current study measured all clotting
factors without first freezing samples prior to analysis thus
eliminating effects of an additional freeze–thaw step.
CONCLUSION
Coagulation factor activities were not affected by frozen
storage duration of almost 7 years. Future research will
determine at which cut-off −80°C shelf life, the quality of
DFP is reduced compared to 1 year −30°C stored FFP.
Clotting factor activity in cold-stored thawed AB DFP still
meets minimum quality guidelines after 14 days and its
quality is similar to plasma quality of other cold-stored
blood components. Therefore 14-day cold-stored thawed
AB DFP can be implemented for the early treatment of
major hemorrhage.
ACKNOWLEDGMENTS
The authors wish to thank KJCM Thielen, Sgt1 SAG Petrelli, Sgt.
LJHC Boudewijns, and Sgt. JW Buis for their technical assistance.
CONFLICTS OF INTEREST




1. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of
plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio
and mortality in patients with severe trauma: the PROPPR ran-
domized clinical trial. JAMA 2015;313:471-82.
2. Roback JD, Caldwell S, Carson J, et al. Evidence-based prac-
tice guidelines for plasma transfusion. Transfusion 2010;50:
1227-39.
3. Sperry JL, Guyette FX, Brown JB, et al. Prehospital plasma dur-
ing air medical transport in trauma patients at risk for hemor-
rhagic shock. N Engl J Med 2018;379:315-26.
4. Teixeira PG, Inaba K, Shulman I, et al. Impact of plasma trans-
fusion in massively transfused trauma patients. J Trauma 2009;
66:693-7.
5. Menzies Wojtowicz M, Motum P, Dhir V (2020). Extended life
plasma: blood wastage and opportunities. Transfus Med, 30(2),
161–163.
6. Downes KA, Wilson E, Yomtovian R, et al. Serial measurement
of clotting factors in thawed plasma stored for 5 days. Transfu-
sion 2001;41:570.
7. Lamboo M, Poland DC, Eikenboom JC, et al. Coagulation
parameters of thawed fresh-frozen plasma during storage at
different temperatures. Transfus Med 2007;17:182-6.
8. von Heymann C, Keller MK, Spies C, et al. Activity of clotting
factors in fresh-frozen plasma during storage at 4 degrees C
over 6 days. Transfusion 2009;49:913-20.
9. Sheffield WP, Bhakta V, Yi Q-L, et al. Stability of thawed aphe-
resis fresh-frozen plasma stored for up to 120 hours at 1°C to
6°C. J Blood Transfus 2016;2016:6260792.
10. Neisser-Svae A, Trawnicek L, Heger A, et al. Five-day stability
of thawed plasma: solvent/detergent-treated plasma compara-
ble with fresh-frozen plasma and plasma frozen within 24
hours. Transfusion 2016;56:404-9.
11. Keller MK, Krebs M, Spies C, et al. Clotting factor activity in
thawed Octaplas(R) LG during storage at 2-6 degrees C for
6 days from a quality assurance point of view. Transfus Apher
Sci 2012;46:129-36.
12. Noordin SS, Karim FA, Mohammad W, et al. Coagulation factor
activities changes over 5 days in thawed fresh frozen plasma
stored at different initial storage temperatures. Ind J Hematol
Blood Transfus 2018;34:510-6.
13. Matijevic N, Kostousov V, Y-WW W, et al. Multiple levels of
degradation diminish hemostatic potential of thawed plasma. J
Trauma 2011;70:71-80.
14. Buchta C, Felfernig M, Höcker P, et al. Stability of coagulation
factors in thawed, solvent/detergent-treated plasma during
storage at 4 °C for 6 days. Vox Sang 2004;87:182-6.
15. Noorman F, van Dongen TT, Plat MJ, et al. Transfusion: −80
degrees C frozen blood products are safe and effective in mili-
tary casualty care. PLoS One 2016;11:e0168401.
16. Lelkens CC, Koning JG, de Kort B, et al. Experiences with fro-
zen blood products in The Netherlands military. Transfusion
Apher Sci 2006;34:289-98.
17. Holley A, Marks DC, Johnson L, et al. Frozen blood products:
clinically effective and potentially ideal for remote Australia.
Anaesth Intensive Care 2013;41:10-9.
18. European Committee (Partial Agreement) on Blood Transfu-
sion (CD-P-TS ). Guide to the preparation, use and quality
assurance of blood components. 19th ed.; 2017). Strasbourg:
Council of Europe.
19. Lacroix R, Judicone C, Mooberry M, et al. Standardization of
pre-analytical variables in plasma microparticle determination:
results of the International Society on Thrombosis and
Haemostasis SSC Collaborative workshop. J Thromb Haemost
2013;11:1190-3.
20. Radwan ZA, Bai Y, Matijevic N, et al. An emergency depart-
ment thawed plasma protocol for severely injured patients.
JAMA Surg 2013;148:170-5.
21. Jehan F, Aziz H, O’Keeffe T, et al. The role of four-factor pro-
thrombin complex concentrate in coagulopathy of trauma: a
propensity matched analysis. J Trauma Acute Care Surg 2018;
85:18-24.
22. Rizoli SB, Scarpelini S, Callum J, et al. Clotting factor deficiency
in early trauma-associated coagulopathy. J Trauma 2011;
71Suppl 1:S427-34.
23. Valeri CR, Ragno G. The effect of storage of fresh-frozen
plasma at −80 degrees C for as long as 14 years on plasma
clotting proteins. Transfusion 2005;45:1829-30.
24. Acker JP, Marks DC, Sheffield WP. Quality assessment of
established and emerging blood components for transfusion. J
Blood Transfus 2016;2016:4860284.
25. NationalBloodService. Guidelines for the blood transfusion ser-
vices in the United Kingdom. 8th ed. Norwich: TSO (The
Stationery Office); 2013.
26. Sheffield WP, Bhakta V, Yi QL, et al. Stability of Thawed Aphe-
resis Fresh-Frozen Plasma Stored for up to 120 Hours at 1
degrees C to 6 degrees C. J Blood Transfus 2016;2016:6260792.
27. Matijevic N, Wang YW, Kostousov V, et al. Decline in platelet
microparticles contributes to reduced hemostatic potential of
stored plasma. Thromb Res 2011;128:35-41.
28. Sheffield WP, Bhakta V, Mastronardi C, et al. Changes in coag-
ulation factor activity and content of di(2-ethylhexyl)phthalate
in frozen plasma units during refrigerated storage for up to five
days after thawing. Transfusion 2012;52:493-502.
29. Yazer MH, Cortese-Hassett A, Triulzi DJ. Coagulation factor
levels in plasma frozen within 24 hours of phlebotomy over
5 days of storage at 1 to 6 degrees C. Transfusion 2008;48:
2525-30.
30. Nifong TP, Light J, Wenk RE. Coagulant stability and sterility of
thawed S/D-treated plasma. Transfusion 2002;42:1581-4.
31. Thiele T, Iuga C, Janetzky S, et al. Early storage lesions in aphe-
resis platelets are induced by the activation of the integrin
alphaIIbbeta(3) and focal adhesion signaling pathways. J Prote-
omics 2012;76 Spec No.:297-315.
32. Murray DJ, Olson J, Strauss R, et al. Coagulation changes dur-
ing packed red cell replacement of major blood loss. Anesthe-
siology 1988;69:839-45.
TRANSFUSION 9
PROLONGED SHELF LIFE OF AB PLASMA
33. Cardigan R, Green L. Thawed and liquid plasma–what do we
know? Vox Sang 2015;109:1-10.
34. Suontaka AM, Silveira A, Soderstrom T, et al. Occurrence of
cold activation of transfusion plasma during storage at +4
degrees C. Vox Sang 2005;88:172-80.
35. Huish S, Green L, Curnow E, et al. Effect of storage of plasma
in the presence of red blood cells and platelets: re-evaluating
the shelf life of whole blood. Transfusion 2019;59:3468-77.
36. Backholer L, Green L, Huish S, et al. A paired comparison of
thawed and liquid plasma. Transfusion 2017;57:881-9.
37. Sampson J, de Korte D. DEHP-plasticised PVC: relevance to
blood services. Transfus Med 2011;21:73-83.
38. Nilsson L, Hedner U, Nilsson IM, et al. Shelf-life of bank blood
and stored plasma with special reference to coagulation fac-
tors. Transfusion 1983;23:377-81.
39. Tholpady A, Monson J, Radovancevic R, et al. Analysis of pro-
longed storage on coagulation Factor (F)V, FVII, and FVIII in
thawed plasma: is it time to extend the expiration date beyond
5 days? Transfusion 2013;53:645-50.
40. Novak DJ, Bai Y, Cooke RK, et al. Making thawed universal donor
plasma available rapidly for massively bleeding trauma patients:
experience from the pragmatic, randomized optimal platelets
and plasma ratios (PROPPR) trial. Transfusion 2015;55:1331-9.
41. Gosselin RC, Marshall C, Dwyre DM, et al. Coagulation profile
of liquid-state plasma. Transfusion 2013;53:579-90.
42. Matijevic N, Wang YW, Cotton BA, et al. Better hemostatic pro-
files of never-frozen liquid plasma compared with thawed fresh
frozen plasma. J Trauma Acute Care Surg 2013;74(1):84-90; dis-
cussion 90-81.
43. Li DY, Zhang HW, Feng QZ, et al. Impacts of leukocyte filtra-
tion and irradiation on coagulation factors in fresh frozen
plasma. Exp Ther Med 2015;9:598-602.
44. Afifi OAH, Abdelsalam EMN, Makhlouf A, et al. Evaluation of
coagulation factors activity in different types of plasma prepa-
rations. Indian J Hematol Blood Transfus 2019;35:551-6.
45. Rijnhout TWH, Noorman F, Bek A, et al. Massive transfusion in
The Netherlands. Emerg Med J 2020;37:65-72.
46. Liu X, Chen X, Yang J, et al. Association of ABO blood
groups with von Willebrand factor, factor VIII and
ADAMTS-13 in patients with lung cancer. Oncol Lett 2017;
14:3787-94.
47. Bohling SD, Pagano MB, Stitzel MR, et al. Comparison of clot-
based vs chromogenic factor Xa procoagulant phospholipid
activity assays. Am J Clin Pathol 2012;137:185-92.
48. Scott E, Puca K, Heraly J, et al. Evaluation and comparison of
coagulation factor activity in fresh-frozen plasma and 24-hour
plasma at thaw and after 120 hours of 1 to 6 degrees C storage.
Transfusion 2009;49:1584-91.
49. Smith JF, Ness PM, Moroff G, et al. Retention of coagulation
factors in plasma frozen after extended holding at 1-6 degrees
C. Vox Sang 2000;78:28-30.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article.
Appendix S1: Supporting information.
10 TRANSFUSION
RIJNHOUT ET AL.
